Issue: January 2016
November 15, 2015
1 min read

Oral anti-VEGF, anti-PDGF advanced in pipeline of wet AMD treatments

Issue: January 2016
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

LAS VEGAS — Early data from study of orally administered X-82 show promise for treating wet age-related macular degeneration, according to a presentation here.

X-82 (Tyrogenex) is a tyrosine kinase inhibitor (TKI) with both anti-VEGF and anti- platelet-derived growth factor (PDGF) activities.

Nauman A. Chaudhry, MD, presented data from a phase 1 open-label study of 35 patients with wet AMD, in which six treatment regimens at four dose levels of X-82 were evaluated for preliminary safety and efficacy.

Both refractory and treatment naïve patients maintained or improved vision with few or no intravitreal injections needed. No dose-limiting toxicities were found.

Additionally, there was significant proof-of-concept improvement in OCT images and visual acuity outcomes.

The phase 1 trial results support the randomized, double-masked, comparative dose and placebo-controlled phase 2 study of daily dosing of X-82, which is currently underway, Chaudhry said. — by Kristie L. Kahl


Chaudhry NA. Oral VEGF receptor/PDGF receptor inhibitor X-82. Presented at: The Academy of Ophthalmology. Nov. 13, 2015; Las Vegas.


Chaudhry reports he is an equity owner of Eye Formatics.